Opening book details…
Can I read 020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years on EtoBox?
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years by Gavin Giovannoni; Ludwig Kappos; Jerome de Seze; Stephen L Hauser; James Overell; Harold Koendgen; Kalpesh Prajapati; Marianna Manfrini; Qing Wang; Jerry S Wolinsky is a Medicine article available to read on EtoBox.
What is 020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years about?
## Background Efficacy/safety of ocrelizumab in relapsing multiple sclerosis were demonstrated in the OPERA I/II (NCT01247324/NCT01412333) double-blind period (DBP). We assessed the efficacy of switching to or maintaining ocrelizumab after 4 years of the open-label extension (OLE). ## Methods At OLE commencement, patients continued ocrelizumab (OCR-OCR) or switched from interferon-β-1a to OCR (IFN-OCR). Adjusted annualised relapse rate (ARR), time-to-onset of 24-week confirmed disability progression (CDP24) and risk of requiring a walking aid (Expanded Disability Status Scale score ≥6.0) from DBP baseline were analysed. ## Results Among IFN-OCR switchers, ARR decreased year-on-year from 0.2 in the pre-switch year to 0.04 in OLE Year 4; OCR-OCR continuers maintained low ARRs (pre-switch, 0.13; OLE Year 4, 0.05). CDP24 was lower year-on-year in OCR-OCR continuers versus IFN-OCR switchers in the pre-switch year (7.7% vs 12.0%) and at OLE Year 4 (19.2% vs 23.7%); p<0.05 all comparisons. Over the DBP and OLE, risk of requiring a walking aid was 44% lower (p=0.004) in OCR-OCR continuers versus IFN-OCR switchers. ## Conclusions After 6 years of follow-up, rates of patients with CDP24 and
Who reads 020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Gavin Giovannoni; Ludwig Kappos; Jerome de Seze; Stephen L Hauser; James Overell; Harold Koendgen; Kalpesh Prajapati; Marianna Manfrini; Qing Wang; Jerry S Wolinsky
- Publisher
- BMJ
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)